Enzyme-mediated methylthioadenosine depletion as a novel immune checkpoint therapy

dc.contributor.advisorGeorgiou, George
dc.contributor.advisorStone, Everett Monroe, 1971-
dc.contributor.committeeMemberMaynard, Jennifer
dc.contributor.committeeMemberJiang, Ning
dc.contributor.committeeMemberEhrlich, Lauren
dc.creatorGjuka, Donjeta
dc.date.accessioned2024-06-04T02:54:48Z
dc.date.available2024-06-04T02:54:48Z
dc.date.issued2021-05
dc.date.submittedMay 2021
dc.date.updated2024-06-04T02:54:49Z
dc.description.abstractMethylthioadenosine phosphorylase (MTAP) is an enzyme that is homozygously deleted in approximately 15% of all human cancer types. MTAP deletion has been correlated with cancer progression, poor patient survival, and resistance to immune checkpoint therapies. Frequent MTAP loss in cancer leads to the accumulation of its substrate 5’-deoxy-5’-methylthioadenosine (MTA), which exerts potent immunosuppressive effects in T cells. We hypothesize that accumulated MTA in the tumor microenvironment of MTAP-deficient tumors induces an immunomodulatory effect on surrounding T cells and engenders tumor tolerance. In this dissertation, we explore the therapeutic efficacy of enzyme-mediated MTA depletion in several MTAP-deficient tumor models. Our results indicate that treating MTAP-deficient tumors with MTA-degrading enzymes can drastically suppress tumor growth. Moreover, our in vivo studies and immunophenotyping experiments suggest that the therapeutic benefit of MTA-depletion is mediated by CD8 T cells that infiltrate the tumor microenvironment. Additionally, we tested the combined therapeutic effects of MTA depletion with immune checkpoint therapy (e.g., anti-PD1 or anti-CTLA4) and observed a potent synergistic effect. Furthermore, we investigate MTA’s mechanism of action on T cells. Due to MTA’s structural similarities with adenosine, we examined putative signaling of MTA through adenosine receptors. Our findings show that adenosine signaling is not the main pathway that MTA utilizes to suppress T cells. Instead, our proteomics analysis of T cells incubated with MTA suggest that MTA inhibits T cells, at least in part, via the differential expression of methyltransferase/demethylase enzymes, upregulation of proapoptotic proteins, and inhibition of proteins crucial for TCR activation and cytokine signaling. In this work, we also discuss the engineering and optimization of the MTAP enzyme for therapeutic use. Collectively, this dissertation elucidates the suppression mechanism of MTA on T cells and demonstrates the potential of utilizing MTA-depletion therapy as a biomarker-driven (namely, MTAP status) immunotherapeutic modality.
dc.description.departmentCellular and Molecular Biology
dc.format.mimetypeapplication/pdf
dc.identifier.uri
dc.identifier.urihttps://hdl.handle.net/2152/125652
dc.identifier.urihttps://doi.org/10.26153/tsw/52213
dc.subjectImmune checkpoint therapy
dc.subjectT cells
dc.subjectCancer
dc.subjectEnzyme engineering
dc.subjectImmunology
dc.titleEnzyme-mediated methylthioadenosine depletion as a novel immune checkpoint therapy
dc.typeThesis
dc.type.materialtext
local.embargo.lift2022-05-01
local.embargo.terms2022-05-01
thesis.degree.departmentCellular and Molecular Biology
thesis.degree.grantorThe University of Texas at Austin
thesis.degree.nameDoctor of Philosophy
thesis.degree.programCell and Molecular Biology

Access full-text files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
GJUKA-PRIMARY-2024-1.pdf
Size:
8.35 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
LICENSE.txt
Size:
1.84 KB
Format:
Plain Text
Description: